GlassScriptPhysician profile
Javier Gutierrez
NPI 1891955373
$1,058.55
in general payments reported to CMS, 2019-2025
21 companies · $485 in 2025
The $485 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $188 · 2021: $12.50 · 2023: $20.03 · 2024: $353 · 2025: $485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $858.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $857.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $268.25 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $133.47 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $119.20 | 2024-2025 | Airsupra |
| Amgen INC. | $101.59 | 2019-2025 | Prolia, Evenity, Otezla |
| Abbott Laboratories | $64.21 | 2019-2025 | Freestyle Libre 3 |
| Grifols USA, LLC | $56.28 | 2025 | Prolastin-C Liquid |
| Otsuka America Pharmaceutical, INC. | $33.87 | 2025 | Rexulti |
| Abbvie INC. | $31.01 | 2024 | |
| Corcept Therapeutics | $26.29 | 2025 | Korlym |
| Pfizer INC. | $25.86 | 2025 | |
| Dexcom, INC. | $23.64 | 2024 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $21.58 | 2025 | Wavewriter Alpha Prime 16 |
| Actelion Pharmaceuticals US, INC. | $21.04 | 2024 | Uptravi, Opsumit |
| Sumitomo Pharma America, INC. | $20.09 | 2025 | Gemtesa |
| Ionis Pharmaceuticals, INC. | $18.52 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $18.51 | 2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $16.34 | 2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $16.24 | 2025 | |
| Irhythm Technologies, INC. | $15.00 | 2024 | Zio Xt Patch |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.49 | 2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $13.07 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javier Gutierrez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.